» Articles » PMID: 20450491

Pleiotropic Mechanisms Facilitated by Resveratrol and Its Metabolites

Overview
Journal Biochem J
Specialty Biochemistry
Date 2010 May 11
PMID 20450491
Citations 69
Authors
Affiliations
Soon will be listed here.
Abstract

Resveratrol has demonstrated cancer chemopreventive activity in animal models and some clinical trials are underway. In addition, resveratrol was shown to promote cell survival, increase lifespan and mimic caloric restriction, thereby improving health and survival of mice on high-calorie diet. All of these effects are potentially mediated by the pleiotropic interactions of resveratrol with different enzyme targets including COX-1 (cyclo-oxygenase-1) and COX-2, NAD+-dependent histone deacetylase SIRT1 (sirtuin 1) and QR2 (quinone reductase 2). Nonetheless, the health benefits elicited by resveratrol as a direct result of these interactions with molecular targets have been questioned, since it is rapidly and extensively metabolized to sulfate and glucuronide conjugates, resulting in low plasma concentrations. To help resolve these issues, we tested the ability of resveratrol and its metabolites to modulate the function of some known targets in vitro. In the present study, we have shown that COX-1, COX-2 and QR2 are potently inhibited by resveratrol, and that COX-1 and COX-2 are also inhibited by the resveratrol 4'-O-sulfate metabolite. We determined the X-ray structure of resveratrol bound to COX-1 and demonstrate that it occupies the COX active site similar to other NSAIDs (non-steroidal anti-inflammatory drugs). Finally, we have observed that resveratrol 3- and 4'-O-sulfate metabolites activate SIRT1 equipotently to resveratrol, but that activation is probably a substrate-dependent phenomenon with little in vivo relevance. Overall, the results of this study suggest that in vivo an interplay between resveratrol and its metabolites with different molecular targets may be responsible for the overall beneficial health effects previously attributed only to resveratrol itself.

Citing Articles

The potential of natural products to inhibit abnormal aggregation of α-Synuclein in the treatment of Parkinson's disease.

Yang K, Lv Z, Zhao W, Lai G, Zheng C, Qi F Front Pharmacol. 2024; 15:1468850.

PMID: 39508052 PMC: 11537895. DOI: 10.3389/fphar.2024.1468850.


Activation and inhibition of sirtuins: From bench to bedside.

Fiorentino F, Fabbrizi E, Mai A, Rotili D Med Res Rev. 2024; 45(2):484-560.

PMID: 39215785 PMC: 11796339. DOI: 10.1002/med.22076.


REsveratrol for VAscular cognitive impairment investigating cerebral Metabolism and Perfusion (REVAMP trial): a study protocol for a randomized, double-blind, placebo-controlled trial.

Hattori Y, Minami M, Omae K, Yoshimoto T, Abe S, Yamamoto H Front Nutr. 2024; 11:1359330.

PMID: 38716073 PMC: 11074349. DOI: 10.3389/fnut.2024.1359330.


-Stilbenes: General Chemical and Biological Aspects, Potential Pharmacological Activity Based on the Nrf2 Pathway.

Mendonca E, Xavier J, Fragoso M, Silva M, Escodro P, Oliveira A Pharmaceuticals (Basel). 2024; 17(2).

PMID: 38399446 PMC: 10891666. DOI: 10.3390/ph17020232.


Curcumin and Resveratrol: Nutraceuticals with so Much Potential for Pseudoachondroplasia and Other ER-Stress Conditions.

Posey K Biomolecules. 2024; 14(2).

PMID: 38397390 PMC: 10886985. DOI: 10.3390/biom14020154.


References
1.
Zykova T, Zhu F, Zhai X, Ma W, Ermakova S, Lee K . Resveratrol directly targets COX-2 to inhibit carcinogenesis. Mol Carcinog. 2008; 47(10):797-805. PMC: 2562941. DOI: 10.1002/mc.20437. View

2.
Buryanovskyy L, Fu Y, Boyd M, Ma Y, Hsieh T, Wu J . Crystal structure of quinone reductase 2 in complex with resveratrol. Biochemistry. 2004; 43(36):11417-26. PMC: 3650734. DOI: 10.1021/bi049162o. View

3.
Zahid M, Gaikwad N, Ali M, Lu F, Saeed M, Yang L . Prevention of estrogen-DNA adduct formation in MCF-10F cells by resveratrol. Free Radic Biol Med. 2008; 45(2):136-45. PMC: 2494714. DOI: 10.1016/j.freeradbiomed.2008.03.017. View

4.
Pacholec M, Bleasdale J, Chrunyk B, Cunningham D, Flynn D, Garofalo R . SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem. 2010; 285(11):8340-51. PMC: 2832984. DOI: 10.1074/jbc.M109.088682. View

5.
Cuendet M, Mesecar A, DeWitt D, Pezzuto J . An ELISA method to measure inhibition of the COX enzymes. Nat Protoc. 2007; 1(4):1915-21. DOI: 10.1038/nprot.2006.308. View